<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635306</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-CD-041</org_study_id>
    <nct_id>NCT04635306</nct_id>
  </id_info>
  <brief_title>13C-Spirulina Nitrogen Content GEBT Study</brief_title>
  <official_title>Determination of the Effect of 13C-Spirulina Nitrogen Content on In-vivo 13C-Spirulina Gastric Emptying Breath Test (GEBT) Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairn Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairn Diagnostics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is a difference in the human in vivo&#xD;
      response to 13C-Spirulina meals manufactured using 13C-Spirulina containing different levels&#xD;
      of protein (as measured by %nitrogen).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study participants will be administered the standard FDA-approved GEBT in which the&#xD;
      test meals contain 13C-Spirulina that has 7.9% Nitrogen content. On a second occasion, a low&#xD;
      nitrogen GEBT in which the test meal will contain 13C-Spirulina with a 6.4% Nitrogen content&#xD;
      will be administered. Both sets of GEBTs have been manufactured under full cGMPs and both&#xD;
      will be administered to the participants according to the FDA-approved GEBT labeling. The two&#xD;
      in vivo results of the two independent GEBT test administrations in the study cohort will be&#xD;
      compared to determine whether there is any significant different in in vivo 13CO2 signaling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Initial results showed no equivalence between GEBT test meals with low nitrogen versus a&#xD;
    standard GEBT test meal&#xD;
  </why_stopped>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Actual">June 25, 2021</completion_date>
  <primary_completion_date type="Actual">June 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in vivo 13C-Spirulina GEBT response</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Determining the difference between measure gastric emptying rate (kPCD) results produced from the low %N 13C-Spirulina GEBT test meal and the FDA-approved test meal</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Low Nitrogen GEBT test meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEBT test meal containing low %N content (below 7%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Approved GEBT test meal</intervention_name>
    <description>FDA-approve GEBT test meal</description>
    <arm_group_label>Low Nitrogen GEBT test meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, 18-85 years old at time of signing consent form&#xD;
&#xD;
          -  Ability to eat test meal and provide breath samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or physical exam suggestive of systemic disease such as diabetes mellitus or&#xD;
             pathophysiologic disorders such as renal failure, chronic heart disease, chronic&#xD;
             respiratory disease, liver disease or malabsorption syndrome&#xD;
&#xD;
          -  Symptoms consistent with delayed gastric emptying&#xD;
&#xD;
          -  History of abdominal surgery except appendectomy&#xD;
&#xD;
          -  Use of any medications that may alter gastric motility within two days of the study&#xD;
&#xD;
          -  Use of narcotics or anticholinergics within two days of the study&#xD;
&#xD;
          -  Females on hormone replacement therapy other than birth control medications&#xD;
&#xD;
          -  Receipt of an investigational drug within 4 weeks of the study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Intolerance or allergy to any component of Gastric Emptying Breath Test meal&#xD;
&#xD;
          -  History of neurologic or psychiatric disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Ryder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairn Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairn Diagnostics</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroenterology</keyword>
  <keyword>Gastric emptying breath test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04635306/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

